Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer

Author： Zhu Andrew   Clark Jeffrey   Ryan David   Meyerhardt Jeffrey   Enzinger Peter   Earle Craig   Fuchs Charles   Regan Eileen   Anbe Hiroshi   Houghton Michele   Zhang Joshua   Urrea Peter   Kulke Matthew  

Publisher： Springer Publishing Company

ISSN： 0344-5704

Source： Cancer Chemotherapy and Pharmacology, Vol.59, Iss.3, 2007-03, pp. : 285-293

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Phase I and pharmacokinetic study of Yondelis(TM) (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours

By Twelves C.   Hoekman K.   Bowman A.   Vermorken J.B.   Anthoney A.   Smyth J.   van Kesteren C.   Beijnen J.H.   Uiters J.   Wanders J.   Gomez J.   Guzman C.   Jimeno J.   Hanauske A.   for the New Drug Development Group of the EORTC  

European Journal of Cancer, Vol. 39, Iss. 13, 2003-09 ,pp. : 1842-1851

Elsevier

Access to resources Recommend Favorite

Phase I and pharmacokinetic study of 5-fluorouracil administered by 5-day continuous infusion in patients with hepatocellular carcinoma

By Ueno Hideki   Okada Shuichi   Okusaka Takuji   Ikeda Masafumi   Kuriyama Hitoshi  

Cancer Chemotherapy and Pharmacology, Vol. 49, Iss. 2, 2002-02 ,pp. : 155-160

Springer Publishing Company

Access to resources Recommend Favorite

An EORTC-ECSG phase I study of LU 79553 administered every 21 or 42 days in patients with solid tumours

By Awada A.   Thodtmann R.   Piccart M.J.   Wanders J.   Schrijvers A.H.G.J.   Von Broen I.-M.   Hanauske A.R.  

European Journal of Cancer, Vol. 39, Iss. 6, 2003-04 ,pp. : 742-747

Elsevier

Access to resources Recommend Favorite

Final results of a phase I and pharmacokinetic study of γ-methylene-10-deazaaminopterin (MDAM) administered intravenously daily for five consecutive days in patients with solid tumors

By Johansen Mary   Zukowski Thomas   Hoff Paulo   Newman Robert   Ni Dan   Hutto Toni   Abbruzzeese James   Berghorn Elmer   Hausheer Frederick   Madden Timothy  

Cancer Chemotherapy and Pharmacology, Vol. 53, Iss. 5, 2004-05 ,pp. : 370-376

Springer Publishing Company

Access to resources Recommend Favorite

A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer

By O’Connor R.   O’Leary M.   Ballot J.   Collins C.   Kinsella P.   Mager D.   Arnold R.   O’Driscoll L.   Larkin A.   Kennedy S.   Fennelly D.   Clynes M.   Crown J.  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 1, 2007-01 ,pp. : 79-87

Springer Publishing Company

Access to resources Recommend Favorite